Micro Developing Active

Eli Lilly, 장기 성장을 위해 Zepbound 접근성 확대

점수
0.5
모멘텀
▲ 0.0
기사
9
출처
4

요약

해당 기사는 Eli Lilly의 Zepbound 접근성 확대와 장기 성장 전망을 논의하는 경우 이 서술에 속합니다.

관련 기사

Jim Cramer Likes Eli Lilly’s (LLY) New Deal

Yahoo Finance · 4월 05, 2026
Mixed

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

Nasdaq · 4월 04, 2026
Mixed

Eli Lilly secures long-awaited FDA approval for its obesity pill. Here's what to know

CNBC · 4월 01, 2026
Mixed

The cutthroat battle for the US weight-loss drug market

BBC Business · 3월 23, 2026
Mixed

Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook

Yahoo Finance · 3월 22, 2026
Mixed

출처

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of … Nasdaq
Jim Cramer Likes Eli Lilly’s (LLY) New Deal Yahoo Finance
Is Eli Lilly and Company (LLY) The Best Pharma Stock … Yahoo Finance
Eli Lilly secures long-awaited FDA approval for its obesity pill. … CNBC
Eli Lilly reaches $2.75 billion deal with Insilico to bring … CNBC
Here's How Much Upside Eli Lilly Stock Has, According to … Yahoo Finance
The cutthroat battle for the US weight-loss drug market BBC Business
Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing … Yahoo Finance

타임라인

최종 업데이트 3월 22, 2026